Research programme: gastrointestinal disorder therapeutics - Lyric Pharmaceuticals
Latest Information Update: 23 Aug 2023
Price :
$50 *
At a glance
- Originator Lyric Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Gastrointestinal disorders in USA (unspecified route)
- 28 Mar 2019 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA
- 26 Feb 2015 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)